Complications Trial (DCCT), the American Diabetes Association (ADA) now recommends tight control of blood glucose to near-normal concentrations as the primary goal for most eligible insulin-dependent diabetic patients. In the DCCT, intensive therapeutic intervention was based on frequent self-monitoring of blood glucose and monthly measurements of glycohemoglobin. The importance of glycohemoglobin assessments serves to highlight the present inadequacies in laboratory measurements of this analyte, which hinders wide implementation of the ADA recommendations.
relationship
between the degree of blood glucose control and the risk of late renal, retinal, and neurological complications in patients with insulin-dependent diabetes (IDDM).
The DCCT study of 1441 patients evaluated the effects of conventional vs intensive blood glucose control regimes over an average of >6 years. The goal in the intensive therapy group was to maintain near-normal concentrations of blood glucose. This was achieved by self-monitoring of blood glucose and injections of insulin at least four times daily, and required highly motivated patients who interacted frequently with a team of health care workers. Patients were seen by a physician once a month, at which time blood glucose control was confirmed by measurement of glycohemoglobin (glib). At the end of the study the intensive therapy group revealed 34-76% lower incidence of clinically meaningful retinopathy, 60% less neuropathy, and 56% less albuminuria than controls treated conventionally, albeit at the cost of a threefold increase in severe hypoglycemic episodes (4) .
On the basis of these data, the American Diabetes Association (ADA) now recommends as optimum therapy for eligible insulin-dependent diabetics, blood glucose control at least equal to that achieved in the intensive therapy cohort, and furthermore suggests that the same may be true for patients with non-insulin dependent diabetes (NIDDM) (5). Similar intervention has been previously recommended for GDM (6 
Chemistryof Protein Glycation
Protein glycation starts with the nonenzymatic, reversible condensation of a sugar aldehyde or ketone group with a free, protein-derived amino group to form a labile Schiff base. Equilibrium is reached within a few hours and is proportional to the ambient glucose concentration. Sehiff-base adducts rearrange slowly to form more-stable ketoamine "Amadori" products, taking 4-6 weeks to reach equilibrium (7). Amadori products may undergo further irreversible rearrangements over a penod of months, reacting with free amino groups to form fluorescent cross-linked advanced glycation end (AGE) products. These structures are highly heterogeneous and are readily detected on proteins such as Hb and collagen. They accumulate with age, reflect increased blood glucose, and are increased in patients with poorly controlled diabetes mellitus. AGE products on basement membrane proteins are believed by some investigators to disrupt normal vascular function and to be a major contributing factor in the genesis of late diabetic complications (12). If it is true that protein glycation plays an etiological role in diabetic vascular disease, then this may provide a pathophysiological basis for the clinical observation that the average gHb concentration is directly related to the risk of late diabetic retinopathy (4).
The proportion of a given protein that carries an Amadori product is related to the half-life of the protein and the blood glucose concentration integrated over time. On extracellular molecules the glycated products are derived almost exclusively from glucose, whereas intracellular proteins may react with many different native and phosphorylated sugars. However, in cells that are freely permeable to glucose, such as erythrocytes (RBCs), the major source of glycation products is glucose (7) .
Glycohemoglobin
Glycation may occur at several amino acid residues on various types of Hb (e.g., HbA, A2, and F), and the products are termed glib or glycated Hb. In particular, ion-exchange chromatography, electrophoretic separation, affinity chromatography with phenylboronate matrices, or newly developed immunoassays based on monoclonal antibody technology. These assays differ widely in accuracy and precision and lack standardization, so that results are both method-and laboratoryspecific (for recent comprehensive reviews see references [8] [9] [10] [11] .
In the DCCT this problem was well recognized and avoided by the use of a single central laboratory for all HbA1C assessments. CAP Glib assay technology is advancing rapidly, with the development of fully automated assays that can provide accurate and precise results in either the clinical laboratory or the physician's office. Despite these advances, however, the question remains whether gHb by itself provides the best index for monitoring diabetic control on a frequent basis.
Glycated Serum Proteins
if patients are to be monitored at intervals of <6-8 weeks, there may be a need for assays that are more sensitive than glib to shorter-term fluctuations in blood glucose concentrations.
This applies particularly to GDM, where short-term blood glucose control critically affects fetal well-being and the risk of congenital abnormalities (2). Furthermore, pregnancy may affect the rate of turnover of RBCs and the proportion of maternal HbF, rendering glib measurements difficult to interpret in pregnant women (20, 22) . These problemshave led to the development of assays of glycated serum proteins. Many of these proteins have half-lives of 1-4 weeks, and the extent of their glycation reflects the mean plasma glucose concentrations over the preceding 2-3 weekswith the caveat that gross changes in protein concentration and half-life may have large effects on the proportion of protein that is glycated. Thus, results obtained may be invalid in the presence of cirrhosis of the liver, nephrotic syndrome, dysproteinemias, or after rapid changes in acute-phase reactants (23) . It is not surprising that the first generation of fructosamine assays has not found general favor, given the number of major problems identified in the original assays. These include an apparent lack of specificity for glycated proteins (as much as 60% of any given result was found to be due to nonfructosamine reducing substances, now known to include urates); a lack of standardization among laboratories; difficulty in calibrating the assay; and susceptibility to interference by hyperlipidemia, common in patients with diabetes (27-30 Several authors have explored alternative ways to measure serum protein glycation. The best documented of these is phenylboronate-affinity chromatography separation of glycated and native proteins, followed by assessment of total or specific proteins. Some debate has been generated whether total or individual serum proteins, each with its own half-life, should be measured: Immunoglobulins (36) 
Conclusions
With the release of data from the DCCT (4), and as confirmed by European studies and metaanalysis (43, 44) , it is now apparent that tight blood glucose control should be the goal for all eligible IDDM, and possibly also NIDDM, patients.
As previously observed with GDM, the evidence for the benefit of maintaining nearnormal blood glucose concentrations in diabetic patients without specific contraindications seems incontrovertible. A major limiting factor in implementing these recommendations is likely to be the additional cost, and the onus is thus on the medical profession to develop inexpensive systems for monitoring and treating diabetic patients.
Clinical laboratories can respond by rapidly adopting fully automated, standardized measurements of glib that will significantly assist in the interpretation of this assessment.
The advantages of interlaboratory calibration and standardization are now well documented (8-
11, 45
). In addition, the potential utility of assays of glycated serum proteins should be reevaluated in future trials of intensive therapy regimes. While it is probable that glib measurements will remain a central part of such programs, preliminary studies indicate that during rapid changes in blood glucose control, and especially in pregnancy (46, 47), assays of glycated serum proteins may provide important additional information. The DCCT data suggest that the gHb concentration is directly related to the risk of late complications such as retinopathy (4) and may be inversely related to the risk of severe hypoglycemia.
Fine-tuning of long-term blood glucose control with the aid of both glib and glycated serum protein assays may take on a major role in alleviating the morbidity of a disease that remains a major scourge of modern society. D.B.S. is supported in part by research grant DK 43682 from the National Institutes of Health.
